USS Investment Management Ltd Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Posted by George Bondi on Jun 15th, 2026

USS Investment Management Ltd raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,315 shares of the biopharmaceutical company’s stock after purchasing an additional 1,035 shares during the quarter. USS Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $14,914,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC raised its position in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares during the period. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares during the period. MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the period. CYBER HORNET ETFs LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.0% in the 4th quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 17 shares during the period. Finally, Meyer Handelman Co. raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after buying an additional 18 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Sanford C. Bernstein cut their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Finally, Royal Bank Of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

Get Our Latest Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

REGN opened at $612.14 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $503.25 and a 12 month high of $821.11. The stock has a market capitalization of $64.72 billion, a price-to-earnings ratio of 14.92, a PEG ratio of 1.34 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The business has a fifty day moving average price of $692.11 and a 200 day moving average price of $738.00.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the firm posted $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.